Premium
Suppressor pathways in tumor immunity: A requirement for Qa‐1 positive tumor‐bearer spleen t cells in suppression of the afferent immune response to tumor antigens
Author(s) -
Mulé James J.,
Stanton Thomas H.,
Hellström Ingegerd,
Hellström Karl Erik
Publication year - 1981
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910280315
Subject(s) - spleen , immune system , antigen , suppressor , immunity , cellular immunity , methylcholanthrene , cancer research , immunology , biology , lymph , tumor antigen , activator (genetics) , medicine , pathology , immunotherapy , cancer , receptor , carcinogen , genetics
Spleen cells from mice bearing large methylcholanthrene (MCA)‐induced sarcomas were injected intravenously into mice challenged in the hind footpads with heavily‐irradiated cells from the same or a different sarcoma. As measured by [ 3 H]‐thymidine incorporation on day 5 or 6, cellular proliferation in the draining popliteal lymph nodes of these mice was significantly depressed as compared to control animals receiving normal spleen cells or medium intravenously. The suppression was found to be mediated by a Qa‐1‐positive, Thy‐1‐positive cell. It was relatively resistant to cyclophosphamide treatment (100 mg/kg). Furthermore, it had both antigen‐specific and non‐specific components. The findings are discussed in relation to a suppressor activator cellsuppressor acceptor cell pathway in the immunoregulation of tumor immunity.